Recurrent and clonal genetic alterations in different subtypes of Acute Lymphoblastic Leukemia (ALL) are well-characterized and known to be strong independent predictors of disease outcome. The conventional SALSA^® MLPA^® technology is one of the standard methods for the detection of IKZF1 deletions, which are associated with unfavorable outcome in childhood ALL. To increase genomic coverage, the newer SALSA^® digitalMLPA™ technology was employed to create a novel, all-encompassing ALL panel: SALSA^® digitalMLPA Probemix D007 Acute Lymphoblastic Leukemia.